Vetter Launches Use-Centered Approach to Improve Injections

Article

Vetter anounced the Open Innovation Challenge to examine the applicability of digital trends to injection systems.

Vetter has announced an industry challenge to examine how digital trends can be used in the application of injection systems. The Injection 2.0 program is designed to develop “innovative, future-focused and sustainable solutions” for the injection of medicines that are more streamlined to user needs than current methods by employing a user-centered innovation (UCI) approach.

The challenge, called Injection 2.0, consists of 20 participants in four multi-disciplinary teams who will communicate in injection systems users to create more purposeful injection processes.

Vetter’s Open Innovation Challenge was officially launched on June 7, 2018 at a workshop in Ravensburg, Germany. Ideas resulting from the initiative will be further pursued in the context of Vetter’s innovation process, the company reports in a press statement announcing the program.

Participants, including students, medical and economic professionals, and Vetter staff, will apply Design Thinking, a user-centered innovation method that involves direct communication with users of injection systems, including professional caregivers and patients in healthcare settings such as nursing homes, assisted-living facilities, hospitals, and the home healthcare sector. The campaign will continue until the end of September.

In the first field-work phase, participating teams will interview patients, doctors, and professional caregivers. The information collected will be used to address patient’s conscious and subconscious needs and problems that occur when interacting with injection systems on a regular basis. Based on these results, user-oriented ideas for solutions can be generated.

The Open Innovation Challenge will be conducted with the bwcon Innovation Academy, a European technology network of approximately 600 companies and research establishments.

Source: Vetter

 

Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.